JPMorgan raised the firm’s price target on Gilead (GILD) to $105 from $100 and keeps an Overweight rating on the shares. The company reported a sales beat, driven by strength across the HIV portfolio and better than expected revenues for Veklury, the analyst tells investors in a research note. The firm says Gilead’s HIV business had a strong quarter with continued volume growth and favorable mix.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $95 from $84 at Barclays
- Gilead Sciences Shows Strong Q3 Results Amid Strategic Initiatives
- Closing Bell Movers: AppLoving up 29% after Q3 earnings beat
- Gilead reports Q3 adjusted EPS $2.02, consensus $1.55
- Gilead raises FY24 EPS view to $4.25-$4.45 from $3.60-$3.90, consensus $3.81